GeneDx Holdings Corp.

Equities

WGS

US81663L2007

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
22.39 ^USD	-6.79%		+10.19%	+714.18%

30/04	Health Care Flat Amid Mixed Earnings -- Health Care Roundup	DJ
30/04	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

GeneDx Holdings Corp. Updates Earnings Guidance for the Year 2024

April 30, 2024 at 01:35 am IST

GeneDx Holdings Corp. updated earnings guidance for the year 2024. For the year, the company now expects revenues to be between $235 million and $245 million (previous guidance was $220 million to $230 million).

Latest news about GeneDx Holdings Corp.

Health Care Flat Amid Mixed Earnings -- Health Care Roundup	01/05	DJ
Sector Update: Health Care Stocks Mixed Late Afternoon	01/05	MT
Top Midday Gainers	01/05	MT
TD Cowen Adjusts GeneDx Holdings' Price Target to $24 From $14, Keeps Buy Rating	30/04	MT
BTIG Adjusts GeneDx Holdings' Price Target to $19 From $15, Keeps Buy Rating	30/04	MT
Transcript : GeneDx Holdings Corp., Q1 2024 Earnings Call, Apr 29, 2024	30/04
GeneDx Holdings Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	30/04	CI
GeneDx Holdings Corp. Updates Earnings Guidance for the Year 2024	30/04	CI
Genedx Announces Partnership with Komodo Health to Expand Access to World?S Largest Rare Disease Dataset	23/04	CI
Goldman Sachs Adjusts GeneDx Holdings Price Target to $11 From $6, Maintains Neutral Rating	15/04	MT
Health Care Down on a Mixed Growth View -- Health Care Roundup	22/02	DJ
Earnings Flash (WGS) GENEDX HOLDINGS Posts Q4 Revenue $57.4M	21/02	MT
Transcript : GeneDx Holdings Corp., Q4 2023 Earnings Call, Feb 20, 2024	21/02
GeneDx Holdings Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	21/02	CI
GeneDx Holdings Corp. Provides Earnings Guidance for the Full Year of 2024	21/02	CI
GeneDx Shares Gain After Preliminary Q4 Revenue Outlook	09/01	MT
Genedx Holdings Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023	08/01	CI
GeneDx Holdings Corp.(NasdaqGS:WGS) dropped from S&P Global BMI Index	18/12	CI
Genedx Holdings Insider Bought Shares Worth $161,368, According to a Recent SEC Filing	21/11	MT
Genedx Holdings Insider Sold Shares Worth $1,140,027, According to a Recent SEC Filing	18/11	MT
Transcript : GeneDx Holdings Corp., Q3 2023 Earnings Call, Oct 30, 2023	31/23/31
Earnings Flash (WGS) GENEDX HOLDINGS Reports Q3 Revenue $53.3M, vs. Street Est of $52.4M	31/23/31	MT
GeneDx Holdings Corp. Updates Revenue Guidance for the Full Year 2023	31/23/31	CI
GeneDx Holdings Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	31/23/31	CI
Genedx Holdings Corp. Announces Executive Appointments	11/23/11	CI

Chart GeneDx Holdings Corp.

Duration

Period

More charts

Company Profile

GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.

Sector

Healthcare Facilities & Services

Calendar

20/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for GeneDx Holdings Corp.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

22.39 USD

Average target price

15.25 USD

Spread / Average Target

-31.89%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
GENEDX HOLDINGS CORP.	+714.18%	628M
SONIC HEALTHCARE LIMITED	-16.99%	8.67B
RADNET, INC.	+65.23%	4.25B
DR. LAL PATHLABS LIMITED	-1.10%	2.51B
SYNLAB AG	-10.68%	2.47B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-41.76%	2.25B
NEOGENOMICS, INC.	-8.53%	1.91B
FLEURY S.A.	-19.29%	1.56B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-39.61%	1.19B
METROPOLIS HEALTHCARE LIMITED	+9.54%	1.15B

Medical & Diagnostic Laboratories